Castle Biosciences/$CSTL
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Castle Biosciences
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
- Ticker
- $CSTL
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 1,002
- Headquarters
- Friendswood, United States
- Website
- castlebiosciences.com
CSTL Metrics
BasicAdvanced
$1.1B
-
-$0.65
0.97
-
Price and volume
Market cap
$1.1B
Beta
0.97
52-week high
$44.28
52-week low
$17.72
Average daily volume
366K
Financial strength
Current ratio
6.036
Quick ratio
5.602
Long term debt to equity
0.069
Total debt to equity
0.078
Interest coverage (TTM)
-32.02%
Profitability
EBITDA (TTM)
-16.516
Gross margin (TTM)
77.26%
Net profit margin (TTM)
-5.43%
Operating margin (TTM)
-3.36%
Effective tax rate (TTM)
-1.10%
Revenue per employee (TTM)
$360,000
Management effectiveness
Return on assets (TTM)
-1.36%
Return on equity (TTM)
-4.20%
Valuation
Price to revenue (TTM)
2.902
Price to book
2.27
Price to tangible book (TTM)
2.84
Price to free cash flow (TTM)
-2,120.66
Free cash flow yield (TTM)
-0.05%
Free cash flow per share (TTM)
-0.016
Growth
Revenue change (TTM)
3.18%
Earnings per share change (TTM)
96.09%
3-year revenue growth (CAGR)
28.72%
3-year earnings per share growth (CAGR)
-42.00%
What the Analysts think about CSTL
Analyst ratings (Buy, Hold, Sell) for Castle Biosciences stock.
Analyst projections of the future price of Castle Biosciences stock.
Bulls say / Bears say
Second-quarter revenue rose 20% year on year, and Castle raised its 2026 revenue outlook to $365–375 million. TissueCypher reports grew 63%, giving the company a fast-growing business beyond its established melanoma test. (Castle Biosciences)
A prospective study of 2,799 patients across 29 US centres found that low-risk results from DecisionDx-Melanoma identified a group with 99.6% five-year recurrence-free survival when patients did not undergo sentinel lymph node biopsy. This evidence may help support clinical adoption of the test. (Castle Biosciences)
Castle ended June with $266.8 million in cash and marketable securities, and reported positive adjusted EBITDA of $12.4 million for the quarter. Management expects positive adjusted EBITDA for the full year and says the balance sheet gives it room to invest in growth. (Castle Biosciences)
Medicare coverage for DecisionDx-SCC was withdrawn in 2025, and second-quarter test reports fell to 4,011 from 4,762 a year earlier. Any recovery depends on a lengthy reconsideration process, leaving this product exposed to reimbursement risk. (Castle Biosciences, Castle Biosciences)
DecisionDx-Melanoma reports grew only 3% year on year in the second quarter, and sequential growth was below the usual seasonal increase. The company said its sales team was dividing attention across three products, creating a risk that its flagship test's momentum remains modest. (The Motley Fool)
Despite higher revenue, Castle posted a $2.1 million second-quarter net loss, and adjusted gross margin fell to 76% from 80% a year earlier. It also used $6.9 million of operating cash in the first half, which highlights the challenge of turning growth into durable cash generation. (Castle Biosciences, Castle Biosciences)
Data summarised monthly by Lightyear AI. Last updated on 2 Nov 2026.
CSTL Financial Performance
Revenues and expenses
CSTL Earnings Performance
Company profitability
Upcoming events
No upcoming events
CSTL News
AllArticlesVideos
Funds containing CSTL
Fund name | Fund size | $CSTL weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.11% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.11% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.11% |
iShares Nasdaq US Biotechnology£BTEK | $1.1B | 0.07% |
iShares Nasdaq US Biotechnology$BTEC | $1.1B | 0.07% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.